Metabolomics reveals increased isoleukotoxin diol (12,13-DHOME) in human plasma after acute intralipid infusion

Journal of Lipid Research

Volumn 53, Issue 9, 2012, Pages 1979-1986

  Edwards, Lindsay M ^a   Lawler, Nathan G ^b   Nikolic, Sonja B ^d   Peters, James M ^a,d   Horne, James ^c   Wilson, Richard ^c   Davies, Noel W ^c   Sharman, James E ^d  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

(9Z) 12,13 dihydroxyoctadec 9 enoic acid; Fatty acid metabolism; Mass spectrometry; Triglycerides

Indexed keywords

12,13 DIHYDROXYOCTADEC 9 ENOIC ACID; INTRALIPID; LEUKOTOXIN; LINOLEIC ACID; MYRISTIC ACID; OLEIC ACID; PALMITOLEIC ACID; STEARIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; FATTY ACID ANALYSIS; FATTY ACID METABOLISM; GLUCOSE INFUSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84864862895     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P027706     Document Type: Article

References (52)

1. Anon. 2011. Intralipid official FDA information, side effects and uses. In. Baxter Healthcare Corporation.
2. Hammond, E. G., L. A. Johnson, C. Su, T. Wang, and P. J. White. 2005. Soybean oil. In Bailey's Industrial Oil and Fat Products. F. Shahidi, editor. John Wiley and Sons, Inc. 577-653.
3. Manavi, M. V. 2010. Lipid infusion as a treatment for local anesthetic toxicity: a literature review. AANA J. 78: 69-78.
4. Mirtallo, J. M., J. F. Dasta, K. C. Kleinschmidt, and J. Varon. 2010. State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann. Pharmacother. 44: 688-700.
5. Minh, T. C., S. R. Oliver, R. L. Flores, J. Ngo, S. Meinardi, M. K. Carlson, J. Midyett, F. S. Rowland, D. R. Blake, and P. R. Galassetti. 2012. Noninvasive measurement of plasma triglycerides and free fatty acids from exhaled breath. J. Diabetes Sci. Technol. 6: 86-101.
6. Sondermeijer, B. M., C. F. Klein Twennaar, J. J. Kastelein, E. J. Franssen, B. A. Hutten, G. M. Dallinga-Thie, E. S. Stroes, E. Fliers, M. T. Twickler, and M. J. Serlie. 2012. Infusion of a lipid emulsion in healthy men decreases the serotonergic response. Neuroendocrinology. 95: 325-331.
7. Al-Shayji, I. A., M. J. Caslake, and J. M. Gill. 2012. Effects of moderate exercise on VLDL and Intralipid kinetics in overweight/obese middle-aged men. Am. J. Physiol. Endocrinol. Metab. 302: E349-E355.
8. Postuma, R., and C. L. Trevenen. 1979. Liver disease in infants receiving total parenteral nutrition. Pediatrics. 63: 110-115. (Pubitemid 9111209)
9. Lashner, B. A., J. B. Kirsner, and S. B. Hanauer. 1986. Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology. 90: 1039-1041. (Pubitemid 16124784)
10. Okada, Y., N. J. Klein, H. K. van Saene, G. Webb, H. Holzel, and A. Pierro. 2000. Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition. Ann. Surg. 231: 276-281. (Pubitemid 30078812)
11. Okada, Y., E. Papp, N. J. Klein, and A. Pierro. 1999. Total parenteral nutrition directly impairs cytokine production after bacterial challenge. J. Pediatr. Surg. 34: 277-280. (Pubitemid 29091432)
12. Waddell, W. R., R. P. Geyer, E. Clarke, and F. J. Stare. 1954. Function of the reticuloendothelial system in removal of emulsified fat from blood. Am. J. Physiol. 177: 90-94.
13. Mancini, A. D., and J. A. Di Battista. 2011. The cardinal role of the phospholipase A(2)/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E(2) (PCPP) axis in inflammostasis. Inflamm. Res. 60: 1083-1092.
14. Holland, D. J., D. Erne, K. Kostner, R. Leano, B. A. Haluska, T. H. Marwick, and J. E. Sharman. 2011. Acute elevation of triglycerides increases left ventricular contractility and alters ventricular-vascular interaction. Am. J. Physiol. Heart Circ. Physiol. 301: H123-H128.
15. Smith, C. A., E. J. Want, G. O'Maille, R. Abagyan, and G. Siuzdak. 2006. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78: 779-787. (Pubitemid 43228585)
16. Dieterle, F., A. Ross, G. Schlotterbeck, and H. Senn. 2006. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal. Chem. 78: 4281-4290.
17. De Meyer, T., D. Sinnaeve, B. Van Gasse, E. Tsiporkova, E. R. Rietzschel, M. L. De Buyzere, T. C. Gillebert, S. Bekaert, J. C. Martins, and W. Van Criekinge. 2008. NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal. Chem. 80: 3783-3790. (Pubitemid 351705882)
18. Barton, R. H., D. Waterman, F. W. Bonner, E. Holmes, R. Clarke, J. K. Nicholson, and J. C. Lindon. 2010. The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Mol. Biosyst. 6: 215-224.
19. Wolf, S., S. Schmidt, M. Muller-Hannemann, and S. Neumann. 2010. In silico fragmentation for computer assisted identification of metabolite mass spectra. BMC Bioinformatics. 11: 148.
20. Dunn, W. B., D. Broadhurst, P. Begley, E. Zelena, S. Francis-McIntyre, N. Anderson, M. Brown, J. D. Knowles, A. Halsall, J. N. Haselden, et al. 2011. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6: 1060-1083.
21. Lindgren, F., B. Hansen, W. Karcher, M. Sjöström, and L. Eriksson. 1996. Model validation by permutation tests: Applications to variable selection. J. Chemometr. 10: 521-532. (Pubitemid 126465336)
22. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 57: 289-300.
23. Böcker, S., M. C. Letzel, Z. Liptak, and A. Pervukhin. 2009. SIRIUS: decomposing isotope patterns for metabolite identification. Bioinformatics. 25: 218-224.
24. Pluskal, T., S. Castillo, A. Villar-Briones, and M. Oresic. 2010. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 11: 395.
25. Holmes, E., P. J. Foxall, M. Spraul, R. D. Farrant, J. K. Nicholson, and J. C. Lindon. 1997. 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease. J. Pharm. Biomed. Anal. 15: 1647-1659. (Pubitemid 27308674)
26. Rane, S. S., and B. D. Anderson. 2008. What determines drug solubility in lipid vehicles: is it predictable? Adv. Drug Deliv. Rev. 60: 638-656.
27. Kind, T., and O. Fiehn. 2006. Metabolomic database annotations via query of elemental compositions: mass accuracy is insufficient even at less than 1 ppm. BMC Bioinformatics. 7: 234.
28. Gipson, G., K. Tatsuoka, B. Sokhansanj, R. Ball, and S. Connor. 2008. Assignment of MS-based metabolomic datasets via compound interaction pair mapping. Metabolomics. 4: 94-103. (Pubitemid 351217593)
29. Moghaddam, M. F., D. F. Grant, J. M. Cheek, J. F. Greene, K. C. Williamson, and B. D. Hammock. 1997. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat. Med. 3: 562-566. (Pubitemid 27198657)
30. Medina-Gomez, G., S. Gray, and A. Vidal-Puig. 2007. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr. 10: 1132-1137. (Pubitemid 350085201)
31. Lecka-Czernik, B., E. J. Moerman, D. F. Grant, J. M. Lehmann, S. C. Manolagas, and R. L. Jilka. 2002. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 143: 2376-2384. (Pubitemid 34521584)
32. Sisemore, M. F., J. Zheng, J. C. Yang, D. A. Thompson, C. G. Plopper, G. A. Cortopassi, and B. D. Hammock. 2001. Cellular characterization of leukotoxin diol-induced mitochondrial dysfunction. Arch. Biochem. Biophys. 392: 32-37. (Pubitemid 32721611)
33. Viswanathan, S., B. D. Hammock, J. W. Newman, P. Meerarani, M. Toborek, and B. Hennig. 2003. Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J. Am. Coll. Nutr. 22: 502-510. (Pubitemid 38010016)
34. Hayakawa, M., K. Kosaka, S. Sugiyama, K. Yokoo, H. Aoyama, Y. Izawa, and T. Ozawa. 1990. Proposal of leukotoxin, 9,10-epoxy-12-octadecenoate, as a burn toxin. Biochem. Int. 21: 573-579. (Pubitemid 20230086)
35. Kosaka, K., K. Suzuki, M. Hayakawa, S. Sugiyama, and T. Ozawa. 1994. Leukotoxin, a linoleate epoxide: its implication in the late death of patients with extensive burns. Mol. Cell. Biochem. 139: 141-148. (Pubitemid 24371163)
36. Fukushima, A., M. Hayakawa, S. Sugiyama, M. Ajioka, T. Ito, T. Satake, and T. Ozawa. 1988. Cardiovascular effects of leukotoxin (9, 10-epoxy-12-octadecenoate) and free fatty acids in dogs. Cardiovasc. Res. 22: 213-218. (Pubitemid 18075572)
37. Sakai, T., T. Ishizaki, T. Ohnishi, F. Sasaki, S. Ameshima, T. Nakai, S. Miyabo, S. Matsukawa, M. Hayakawa, and T. Ozawa. 1995. Leukotoxin, 9,10-epoxy-12-octadecenoate inhibits mitochondrial respiration of isolated perfused rat lung. Am. J. Physiol. 269: L326-L331.
38. Ishizaki, T., K. Shigemori, T. Nakai, S. Miyabo, T. Ozawa, S. W. Chang, and N. F. Voelkel. 1995. Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase. Am. J. Physiol. 269: L65-L70.
39. Morisseau, C., and B. D. Hammock. 2005. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45: 311-333. (Pubitemid 40261808)
40. Ha, J., M. Dobretsov, R. C. Kurten, D. F. Grant, and J. R. Stimers. 2002. Effect of linoleic acid metabolites on Na(+)/K(+) pump current in N20.1 oligodendrocytes: role of membrane fluidity. Toxicol. Appl. Pharmacol. 182: 76-83. (Pubitemid 34775479)
41. Harrell, M. D., and J. R. Stimers. 2002. Differential effects of linoleic acid metabolites on cardiac sodium current. J. Pharmacol. Exp. Ther. 303: 347-355.
42. Markaverich, B. M., M. Alejandro, T. Thompson, S. Mani, A. Reyna, W. Portillo, J. Sharp, J. Turk, and J. R. Crowley. 2007. Tetrahydrofurandiols (THF-diols), leukotoxindiols (LTX-diols), and endocrine disruption in rats. Environ. Health Perspect. 115: 702-708. (Pubitemid 46785039)
43. Markaverich, B. M., J. R. Crowley, M. A. Alejandro, K. Shoulars, N. Casajuna, S. Mani, A. Reyna, and J. Sharp. 2005. Leukotoxin diols from ground corncob bedding disrupt estrous cyclicity in rats and stimulate MCF-7 breast cancer cell proliferation. Environ. Health Perspect. 113: 1698-1704. (Pubitemid 41794264)
44. Thompson, D. A., and B. D. Hammock. 2007. Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst. J. Biosci. 32: 279-291. (Pubitemid 46708725)
45. Hwang, S. H., H. J. Tsai, J. Y. Liu, C. Morisseau, and B. D. Hammock. 2007. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 50: 3825-3840. (Pubitemid 47292046)
46. Simopoulos, A. P. 1999. Evolutionary aspects of omega-3 fatty acids in the food supply. Prostaglandins Leukot. Essent. Fatty Acids. 60: 421-429. (Pubitemid 29401803)
47. Kris-Etherton, P. M., D. S. Taylor, S. Yu-Poth, P. Huth, K. Moriarty, V. Fishell, R. L. Hargrove, G. Zhao, and T. D. Etherton. 2000. Polyunsaturated fatty acids in the food chain in the United States. Am. J. Clin. Nutr. 71 (Suppl.): 179-188.
48. Lutz, O., Z. Meraihi, J. L. Mura, A. Frey, G. H. Riess, and A. C. Bach. 1989. Fat emulsion particle size: influence on the clearance rate and the tissue lipolytic activity. Am. J. Clin. Nutr. 50: 1370-1381. (Pubitemid 20013320)
49. Veech, R. L. 2004. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids. 70: 309-319. (Pubitemid 38200957)
50. Sato, K., Y. Kashiwaya, C. A. Keon, N. Tsuchiya, M. T. King, G. K. Radda, B. Chance, K. Clarke, and R. L. Veech. 1995. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 9: 651-658.
51. Srivastava, S., Y. Kashiwaya, M. T. King, U. Baxa, J. Tam, G. Niu, X. Chen, K. Clarke, and R. L. Veech. 2012. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J. 26: 2351-2362.
52. Kashiwaya, Y., R. Pawlosky, W. Markis, M. T. King, C. Bergman, S. Srivastava, A. Murray, K. Clarke, and R. L. Veech. 2010. A ketone ester diet increases brain malonyl-CoA and uncoupling proteins 4 and 5 while decreasing food intake in the normal Wistar rat. J. Biol. Chem. 285: 25950-25956.